Soligenix CEO Discusses Upcoming Interim Analysis of Phase 3 FLASH2 Study on The BioMedWire Podcast

Thursday, Mar 19, 2026 8:13 am ET1min read
SNGX--

IBN announces the latest episode of The BioMedWire Podcast featuring Dr. Christopher Schaber, CEO of Soligenix Inc. The podcast delivers dynamic interviews with industry experts in pharmaceutical and biotech advancement. Dr. Schaber discussed the upcoming interim analysis of the company's Phase 3 FLASH2 study evaluating HyBryte™ for the treatment of cutaneous T-cell lymphoma. He emphasized the company's upcoming inflection points and the broader significance of the interim and top-line data expected later this year.

Soligenix CEO Discusses Upcoming Interim Analysis of Phase 3 FLASH2 Study on The BioMedWire Podcast

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet